Literature DB >> 16303776

Intravenous immunoglobulin for resistant Clostridium difficile infection.

C Murphy1, M Vernon, M Cullen.   

Abstract

Clostridium difficile (CD)-associated diarrhoea and colitis may relapse in up to 20% of treated patients. We present a patient who failed to respond over a 6-month period to treatment either singly or in combination with metronidazole, vancomycin, rifampicin, cholestyramine and probiotics. Her diarrhoea rapidly resolved after a 3-day course of intravenous immunoglobulin. This treatment may compensate for a failed immune response to CD toxin and should be considered for relapsing CD-associated diarrhoea where there is no response to conventional treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303776     DOI: 10.1093/ageing/afi212

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  6 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

Review 2.  Epidemiology, pathogenesis, and management of Clostridium difficile infection.

Authors:  Rajaraman Durai
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 3.  Treatment of recurrent Clostridium difficile infection: a systematic review.

Authors:  J C O'Horo; K Jindai; B Kunzer; N Safdar
Journal:  Infection       Date:  2013-07-10       Impact factor: 3.553

Review 4.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

5.  Metabolism of bile salts in mice influences spore germination in Clostridium difficile.

Authors:  Jennifer L Giel; Joseph A Sorg; Abraham L Sonenshein; Jun Zhu
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

6.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.